A narcotics-law barrier blocks cannabidiol in the GCC, making stiripentol, with a 71% adjunct responder rate, the de-facto standard instead.

Cannabidiol (Epidiolex), which delivered a 38.9% seizure-reduction result across the GWPCARE trials, is not registered in any GCC state as of this writing. Cannabis-derived products require an exceptional MOH/DHA import license under UAE and KSA federal narcotics law; approval runs at roughly 40-50% of applications at KFSH&RC and takes 3 to 6 months per patient, leaving only an estimated 30-50 patients across the entire GCC on named-patient compassionate use. Fenfluramine (Fintepla), which showed a 62% seizure-reduction result in the STUDIO trials, has SFDA registration pending and is limited to named-patient access at KFSH&RC and Aster DM centres.

Stiripentol (Diacomit), which showed a 71% responder rate as adjunct therapy in the STICLO trial, is imported via Biocodex's GCC distributor and is by far the most widely used Dravet-specific agent in the region, purely because its regulatory pathway is simpler than cannabidiol's or fenfluramine's. The stiripentol-plus-valproate-plus-clobazam backbone is the dominant regimen at GCC specialist centres, reversing the US/EU hierarchy in which cannabidiol is typically the first-choice add-on. SCN1A genetic testing is available at only KFSH&RC, AUH Genetics, Sidra Medicine, and roughly four other centres, against an estimated 600 to 800 Dravet patients regionwide.

A new Dravet therapy competes against a stiripentol backbone, not against cannabidiol.

Five questions this report answers:

Q1 - Why is cannabidiol de-facto inaccessible in the GCC despite its 38.9% seizure-reduction result?

Q2 - How does the stiripentol-anchored GCC prescribing backbone change positioning versus the US/EU hierarchy?

Q3 - Where is SCN1A genetic-testing capacity concentrated across the GCC?

Q4 - Why does stiripentol, not cannabidiol, function as the de-facto Dravet standard of care?

Q5 - What would resolving the narcotics-import regulatory pathway be worth to a new entrant?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #GCC #Stiripentol #Cannabidiol #RareDisease #MarketAccess

Live report page:  https://axlrx.ai/dravet-syndrome/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/